Valeo Financial Advisors LLC Sells 511 Shares of Zoetis Inc. (NYSE:ZTS)

Valeo Financial Advisors LLC trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 6.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,517 shares of the company’s stock after selling 511 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Zoetis were worth $1,225,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ZTS. AustralianSuper Pty Ltd purchased a new stake in Zoetis in the 4th quarter valued at about $5,729,000. GFG Capital LLC raised its stake in shares of Zoetis by 16.3% during the fourth quarter. GFG Capital LLC now owns 1,576 shares of the company’s stock valued at $257,000 after acquiring an additional 221 shares in the last quarter. Asset Planning Inc purchased a new stake in shares of Zoetis in the fourth quarter valued at approximately $58,000. Banque Pictet & Cie SA grew its stake in Zoetis by 0.7% in the fourth quarter. Banque Pictet & Cie SA now owns 2,590,473 shares of the company’s stock worth $422,066,000 after purchasing an additional 18,943 shares in the last quarter. Finally, V Square Quantitative Management LLC increased its holdings in Zoetis by 7.4% during the 4th quarter. V Square Quantitative Management LLC now owns 12,432 shares of the company’s stock worth $2,026,000 after purchasing an additional 857 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of Zoetis stock opened at $157.54 on Friday. The company has a 50 day moving average price of $168.51 and a 200 day moving average price of $178.81. The firm has a market capitalization of $71.07 billion, a P/E ratio of 29.61, a PEG ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Sell-side analysts expect that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is presently 36.56%.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ZTS. Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Piper Sandler cut their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Barclays upped their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average target price of $214.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.